{"transactions":[{"id":1046532,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75721,"kind":"person","name":"Mun-Gavin David C.","position":1,"cik":"0002078965","reported_name":"Mun-Gavin David C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2025-09-08T21:45:44.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are fully vested and exercisable."}],"balance_after":31250,"derivative":{"exercise_price":1.33,"expiration_date":"2035-08-19","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001641172-25-026893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225026893/ownership.xml","form_type":"4"}},{"id":1046535,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Option to purchase Common Stock","published_at":"2025-09-08T21:45:43.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in four equal quarterly installments beginning on January 1, 2026."}],"balance_after":100000,"derivative":{"exercise_price":1.33,"expiration_date":"2035-08-19","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001641172-25-026890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225026890/ownership.xml","form_type":"4"}},{"id":1046534,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Option to purchase Common Stock","published_at":"2025-09-08T21:45:43.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal quarterly installments beginning on January 1, 2025."}],"balance_after":100000,"derivative":{"exercise_price":1.33,"expiration_date":"2035-08-19","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001641172-25-026890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225026890/ownership.xml","form_type":"4"}},{"id":1046533,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Option to purchase Common Stock","published_at":"2025-09-08T21:45:43.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are fully vested and exercisable."}],"balance_after":100000,"derivative":{"exercise_price":1.33,"expiration_date":"2035-08-19","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001641172-25-026890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225026890/ownership.xml","form_type":"4"}},{"id":1046530,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75720,"kind":"person","name":"URBAN ALAN LOUIS","position":1,"cik":"0001534376","reported_name":"URBAN ALAN LOUIS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Common Stock","published_at":"2025-09-08T21:45:41.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal quarterly installments beginning on January 1, 2026."}],"balance_after":50000,"derivative":{"exercise_price":1.33,"expiration_date":"2035-08-19","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001641172-25-026894","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225026894/ownership.xml","form_type":"4"}},{"id":1046529,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75720,"kind":"person","name":"URBAN ALAN LOUIS","position":1,"cik":"0001534376","reported_name":"URBAN ALAN LOUIS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Common Stock","published_at":"2025-09-08T21:45:41.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal quarterly installments beginning on January 1, 2025."}],"balance_after":50000,"derivative":{"exercise_price":1.33,"expiration_date":"2035-08-19","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001641172-25-026894","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225026894/ownership.xml","form_type":"4"}},{"id":1046531,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2025-09-08T21:45:40.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are fully vested and exercisable."}],"balance_after":62500,"derivative":{"exercise_price":1.33,"expiration_date":"2035-08-19","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001641172-25-026891","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225026891/ownership.xml","form_type":"4"}},{"id":1046528,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75719,"kind":"person","name":"Kramer Hilary","position":1,"cik":"0002071192","reported_name":"Kramer Hilary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2025-09-08T21:45:38.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are fully vested and exercisable."}],"balance_after":31250,"derivative":{"exercise_price":1.33,"expiration_date":"2035-08-19","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001641172-25-026892","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225026892/ownership.xml","form_type":"4"}},{"id":1383805,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75720,"kind":"person","name":"URBAN ALAN LOUIS","position":1,"cik":"0001534376","reported_name":"URBAN ALAN LOUIS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Common Stock","published_at":"2024-10-22T01:13:40.000Z","date":"2024-10-17","kind":"grant","planned":false,"acquired":true,"shares":23335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares vest on the monthly anniversary of June 3, 2024 until fully vested, subject to full acceleration in the event the reporting person is involuntarily terminated by the registrant without Cause (as defined in the reporting person's Employment Agreement dated June 7, 2024), resignation by the reporting person for Good Reason (as defined in the reporting person's Employment Agreement dated June 7, 2024), or in the event of a Change in Control (as defined in the registrant's 2022 Omnibus Incentive Plan)."}],"balance_after":23335,"derivative":{"exercise_price":2.11,"expiration_date":"2034-10-16","underlying":"Common Stock","underlying_shares":23335},"source":{"system":"sec-edgar","filing":"0001493152-24-041855","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315224041855/ownership.xml","form_type":"4"}},{"id":1807981,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman/Interim CEO"}}],"security":"Common Stock","published_at":"2023-08-15T23:29:58.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0.287,"value":57400.0,"ownership":{"direct":true},"balance_after":856218,"source":{"system":"sec-edgar","filing":"0001493152-23-029061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223029061/ownership.xml","form_type":"4"}},{"id":1807980,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":62804,"kind":"person","name":"Ohri Manu","position":1,"cik":"0001424683","reported_name":"Ohri Manu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Secretary"}}],"security":"Common Stock","published_at":"2023-08-15T23:26:31.000Z","date":"2023-08-11","kind":"other","planned":false,"acquired":true,"shares":200000,"price":0.287,"value":57400.0,"ownership":{"direct":false,"nature":"By Anarjay Concepts, Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001493152-23-029059","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223029059/ownership.xml","form_type":"4"}},{"id":1807979,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":62804,"kind":"person","name":"Ohri Manu","position":1,"cik":"0001424683","reported_name":"Ohri Manu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Secretary"}}],"security":"Common Stock","published_at":"2023-08-15T23:26:31.000Z","date":"2023-08-11","kind":"other","planned":false,"acquired":false,"shares":200000,"price":0.287,"value":57400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-23-029059","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223029059/ownership.xml","form_type":"4"}},{"id":1807978,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":62804,"kind":"person","name":"Ohri Manu","position":1,"cik":"0001424683","reported_name":"Ohri Manu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Secretary"}}],"security":"Common Stock","published_at":"2023-08-15T23:26:31.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0.287,"value":57400.0,"ownership":{"direct":true},"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001493152-23-029059","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223029059/ownership.xml","form_type":"4"}},{"id":1848400,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2023-06-21T23:58:43.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares vest on the monthly anniversary of May 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct."}],"balance_after":500000,"derivative":{"exercise_price":0.35,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001493152-23-022059","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223022059/ownership.xml","form_type":"4"}},{"id":1922046,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman/Interim CEO"}}],"security":"Common Stock","published_at":"2023-04-11T22:59:39.000Z","date":"2023-04-11","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.5,"value":25000.0,"ownership":{"direct":true},"balance_after":656218,"source":{"system":"sec-edgar","filing":"0001493152-23-011888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223011888/ownership.xml","form_type":"4"}},{"id":1922607,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":62804,"kind":"person","name":"Ohri Manu","position":1,"cik":"0001424683","reported_name":"Ohri Manu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Secretary"}}],"security":"Common Stock","published_at":"2023-04-10T21:26:50.000Z","date":"2023-04-06","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.5,"value":25000.0,"ownership":{"direct":false,"nature":"By Ohri Family Revocable Trust U/A Dated 02/10/2020"},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001493152-23-011772","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223011772/ownership.xml","form_type":"4"}},{"id":2039415,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec Chairman and Interim CEO"}}],"security":"Option to purchase Common Stock","published_at":"2023-02-01T11:05:38.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct, and the reporting person is involuntarily terminated by the registrant."}],"balance_after":500000,"derivative":{"exercise_price":0.837,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001493152-23-003230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223003230/ownership.xml","form_type":"4"}},{"id":2039414,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":62804,"kind":"person","name":"Ohri Manu","position":1,"cik":"0001424683","reported_name":"Ohri Manu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Common Stock","published_at":"2023-02-01T11:02:39.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is involuntarily terminated by the registrant."}],"balance_after":500000,"derivative":{"exercise_price":0.837,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001493152-23-003227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223003227/ownership.xml","form_type":"4"}},{"id":2039413,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":117443,"kind":"person","name":"SHROTRIYA RAJESH C MD","position":1,"cik":"0001193918","reported_name":"SHROTRIYA RAJESH C MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2023-02-01T11:02:39.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct."}],"balance_after":500000,"derivative":{"exercise_price":0.837,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001493152-23-003226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223003226/ownership.xml","form_type":"4"}},{"id":2039412,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2023-02-01T11:01:27.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct."}],"balance_after":500000,"derivative":{"exercise_price":0.837,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001493152-23-003224","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223003224/ownership.xml","form_type":"4"}},{"id":2205925,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. Chair. and Interim CEO"}}],"security":"Option to purchase Common Stock","published_at":"2022-07-20T01:48:20.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":2.48,"exercise_date":"2022-07-15","expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-019876","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019876/ownership.xml","form_type":"4"}},{"id":2205924,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. Chair. and Interim CEO"}}],"security":"Common Stock","published_at":"2022-07-20T01:48:20.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":278058,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":606218,"source":{"system":"sec-edgar","filing":"0001493152-22-019876","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019876/ownership.xml","form_type":"4"}},{"id":2205922,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":117443,"kind":"person","name":"SHROTRIYA RAJESH C MD","position":1,"cik":"0001193918","reported_name":"SHROTRIYA RAJESH C MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2022-07-20T01:46:37.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":361476,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"240,984 shares vest on the date of grant and 120,492 shares vest on January 13, 2023."}],"balance_after":361476,"derivative":{"exercise_price":2.48,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":361476},"source":{"system":"sec-edgar","filing":"0001493152-22-019875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019875/ownership.xml","form_type":"4"}},{"id":2205921,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":117443,"kind":"person","name":"SHROTRIYA RAJESH C MD","position":1,"cik":"0001193918","reported_name":"SHROTRIYA RAJESH C MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2022-07-20T01:46:37.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares vest on the date of grant and on each of September 8, 2022, December 8, 2022 and March 8, 2023."}],"balance_after":50000,"derivative":{"exercise_price":2.48,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-019875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019875/ownership.xml","form_type":"4"}},{"id":2205920,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":117443,"kind":"person","name":"SHROTRIYA RAJESH C MD","position":1,"cik":"0001193918","reported_name":"SHROTRIYA RAJESH C MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2022-07-20T01:46:37.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":2.48,"exercise_date":"2022-07-15","expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-019875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019875/ownership.xml","form_type":"4"}},{"id":2205923,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75720,"kind":"person","name":"URBAN ALAN LOUIS","position":1,"cik":"0001534376","reported_name":"URBAN ALAN LOUIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2022-07-20T01:46:16.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares vest on the date of grant and on each of September 9, 2022, December 9, 2022 and March 9, 2023."}],"balance_after":50000,"derivative":{"exercise_price":2.48,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-019874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019874/ownership.xml","form_type":"4"}},{"id":2205919,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":125332,"kind":"person","name":"Berk Gregory","position":1,"cik":"0001306870","reported_name":"Berk Gregory","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres. of R&D, CMO"}}],"security":"Option to purchase Common Stock","published_at":"2022-07-20T01:44:55.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":2.48,"exercise_date":"2022-07-15","expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-019873","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019873/ownership.xml","form_type":"4"}},{"id":2205916,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":62804,"kind":"person","name":"Ohri Manu","position":1,"cik":"0001424683","reported_name":"Ohri Manu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Secretary"}}],"security":"Option to purchase Common Stock","published_at":"2022-07-20T01:44:26.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"66,666 shares on the date of grant, and 66,667 shares on each February 14, 2023 and 2024."}],"balance_after":200000,"derivative":{"exercise_price":2.48,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-22-019872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019872/ownership.xml","form_type":"4"}},{"id":2205915,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":62804,"kind":"person","name":"Ohri Manu","position":1,"cik":"0001424683","reported_name":"Ohri Manu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Secretary"}}],"security":"Common Stock","published_at":"2022-07-20T01:44:26.000Z","date":"2022-07-15","kind":"other","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Anarjay Concepts, Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001493152-22-019872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019872/ownership.xml","form_type":"4"}},{"id":2205914,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":62804,"kind":"person","name":"Ohri Manu","position":1,"cik":"0001424683","reported_name":"Ohri Manu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Secretary"}}],"security":"Common Stock","published_at":"2022-07-20T01:44:26.000Z","date":"2022-07-15","kind":"other","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-22-019872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019872/ownership.xml","form_type":"4"}},{"id":2205913,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":62804,"kind":"person","name":"Ohri Manu","position":1,"cik":"0001424683","reported_name":"Ohri Manu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Secretary"}}],"security":"Common Stock","published_at":"2022-07-20T01:44:26.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001493152-22-019872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019872/ownership.xml","form_type":"4"}},{"id":2205918,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2022-07-20T01:42:46.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares vest on the date of grant and on each of September 8, 2022, December 8, 2022 and March 8, 2023."}],"balance_after":50000,"derivative":{"exercise_price":2.48,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-019871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019871/ownership.xml","form_type":"4"}},{"id":2205917,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2022-07-20T01:42:46.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":2.48,"exercise_date":"2022-07-15","expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-019871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222019871/ownership.xml","form_type":"4"}},{"id":2399926,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":125332,"kind":"person","name":"Berk Gregory","position":1,"cik":"0001306870","reported_name":"Berk Gregory","relationship":{"director":true}}],"security":"Option to purchase Common Stock","published_at":"2022-02-14T22:10:00.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a grant of options in connection with the reporting person's services as a director. 13rd of the shares underlying the options vest on February 16, 2021, 2022 and 2023."}],"balance_after":50000,"derivative":{"exercise_price":6.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001654954-22-001643","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495422001643/section16.xml","form_type":"4"}},{"id":2399925,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":125332,"kind":"person","name":"Berk Gregory","position":1,"cik":"0001306870","reported_name":"Berk Gregory","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-02-14T22:10:00.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":278058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of shares of restricted stock (\"RSAs\") in connection with the reporting person's services as a director.  1/3rd of the RSAs vest on November 11, 2020, 2021 and 2022.  The reporting person resigned as a director on April 23, 2021."}],"balance_after":278058,"source":{"system":"sec-edgar","filing":"0001654954-22-001643","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495422001643/section16.xml","form_type":"4"}},{"id":2399924,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":117443,"kind":"person","name":"SHROTRIYA RAJESH C MD","position":1,"cik":"0001193918","reported_name":"SHROTRIYA RAJESH C MD","relationship":{"director":true}}],"security":"Option to purchase Common Stock","published_at":"2022-02-14T21:13:36.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares vest on February 16, 2021, 2022 and 2023."}],"balance_after":50000,"derivative":{"exercise_price":6.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001654954-22-001635","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495422001635/section16.xml","form_type":"4"}},{"id":2399923,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":130546,"kind":"person","name":"Choy Gavin","position":1,"cik":"0001905561","reported_name":"Choy Gavin","relationship":{"officer":true,"officer_title":"Acting Chief Financial Officer"}}],"security":"Option to purchase Common Stock","published_at":"2022-02-14T21:09:22.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":227500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% on the date of grant, 33% on 6/1/22 and 34% on 6/1/23, subject to continued service and subject to full acceleration immediately prior to the consummation of a change of control."}],"balance_after":227500,"derivative":{"exercise_price":3.05,"expiration_date":"2031-12-31","underlying":"Common Stock","underlying_shares":227500},"source":{"system":"sec-edgar","filing":"0001654954-22-001631","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495422001631/section16.xml","form_type":"4"}},{"id":2516718,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"10% Senior  Convertible  Debenture","published_at":"2021-11-12T17:01:45.000Z","date":"2021-02-25","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.4,"exercise_date":"2020-06-23","expiration_date":"2021-06-23","underlying":"Common Stock","underlying_shares":9859},"source":{"system":"sec-edgar","filing":"0001654954-21-012057","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421012057/section16.xml","form_type":"4"}},{"id":2516717,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"10% Senior  Convertible  Debenture","published_at":"2021-11-12T17:01:45.000Z","date":"2021-02-25","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the\nDebenture on the maturity date and the Debenture remained outstanding until converted."}],"balance_after":0,"derivative":{"exercise_price":3.4,"exercise_date":"2018-09-07","underlying":"Common Stock","underlying_shares":40243},"source":{"system":"sec-edgar","filing":"0001654954-21-012057","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421012057/section16.xml","form_type":"4"}},{"id":2516716,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase  Common Stock","published_at":"2021-11-12T17:01:45.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3rd of the shares vest on February 16, 2021, 2022 and 2023."}],"balance_after":50000,"derivative":{"exercise_price":6.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001654954-21-012057","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421012057/section16.xml","form_type":"4"}},{"id":2516715,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-12T17:01:45.000Z","date":"2021-02-25","kind":"exercise","acquired":true,"shares":9859,"price":3.4,"value":33520.6,"ownership":{"direct":true},"balance_after":328160,"source":{"system":"sec-edgar","filing":"0001654954-21-012057","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421012057/section16.xml","form_type":"4"}},{"id":2516714,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-12T17:01:45.000Z","date":"2021-02-25","kind":"exercise","acquired":true,"shares":40243,"price":3.4,"value":136826.2,"ownership":{"direct":true},"balance_after":318301,"source":{"system":"sec-edgar","filing":"0001654954-21-012057","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421012057/section16.xml","form_type":"4"}},{"id":2516713,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":75722,"kind":"person","name":"Breen Michael Martin","position":1,"cik":"0001863633","reported_name":"Breen Michael Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-12T17:01:45.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":278058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of shares of restricted stock (\"RSAs\"). 1/3rd of the RSAs vest on January 13, 2021, 2022 and 2023."}],"balance_after":278058,"source":{"system":"sec-edgar","filing":"0001654954-21-012057","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421012057/section16.xml","form_type":"4"}},{"id":2546789,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true}}],"security":"Option to purchase Common Stock","published_at":"2021-10-07T18:47:17.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3rd of the shares vest on February 16, 2021, 2022, and 2023."}],"balance_after":50000,"derivative":{"exercise_price":6.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001654954-21-010887","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421010887/section16.xml","form_type":"4"}},{"id":2546788,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-10-07T18:47:17.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":347572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of shares of restricted stock (\"RSAs\"). 1/3rd of the RSAs vest on November 11 2020, 2021 and 2022."}],"balance_after":352655,"source":{"system":"sec-edgar","filing":"0001654954-21-010887","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421010887/section16.xml","form_type":"4"}},{"id":2546787,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-10-07T18:47:17.000Z","date":"2020-12-22","kind":"purchase","acquired":true,"shares":441,"price":8.73,"value":3849.93,"ownership":{"direct":true},"balance_after":5083,"source":{"system":"sec-edgar","filing":"0001654954-21-010887","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421010887/section16.xml","form_type":"4"}},{"id":2546786,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-10-07T18:47:17.000Z","date":"2020-12-22","kind":"purchase","acquired":true,"shares":1374,"price":8.87,"value":12187.38,"ownership":{"direct":true},"balance_after":4642,"source":{"system":"sec-edgar","filing":"0001654954-21-010887","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421010887/section16.xml","form_type":"4"}},{"id":2546785,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-10-07T18:47:17.000Z","date":"2020-11-16","kind":"purchase","acquired":true,"shares":3268,"price":3.14,"value":10261.52,"ownership":{"direct":true},"balance_after":3268,"source":{"system":"sec-edgar","filing":"0001654954-21-010887","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000165495421010887/section16.xml","form_type":"4"}},{"id":2933883,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-23T21:24:42.000Z","date":"2020-12-22","kind":"sale","acquired":false,"shares":47978,"price":0.4,"value":19191.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":3720000,"source":{"system":"sec-edgar","filing":"0001356710-20-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000003/primary_doc.xml","form_type":"4"}},{"id":2933882,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-23T21:24:42.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":35722,"price":0.34,"value":12145.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":3767978,"source":{"system":"sec-edgar","filing":"0001356710-20-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000003/primary_doc.xml","form_type":"4"}},{"id":2933881,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-23T21:24:42.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":50000,"price":0.33,"value":16500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":3803700,"source":{"system":"sec-edgar","filing":"0001356710-20-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000003/primary_doc.xml","form_type":"4"}},{"id":2933880,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-23T21:24:42.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":50000,"price":0.3,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":3853700,"source":{"system":"sec-edgar","filing":"0001356710-20-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000003/primary_doc.xml","form_type":"4"}},{"id":2938843,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-18T21:24:01.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":50000,"price":0.3,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":". The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":3903700,"source":{"system":"sec-edgar","filing":"0001356710-20-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000002/primary_doc.xml","form_type":"4"}},{"id":2938842,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-18T21:24:01.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":50000,"price":0.31,"value":15500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":". The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":3953700,"source":{"system":"sec-edgar","filing":"0001356710-20-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000002/primary_doc.xml","form_type":"4"}},{"id":2938841,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-18T21:24:01.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":50000,"price":0.3,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":". The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4003700,"source":{"system":"sec-edgar","filing":"0001356710-20-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000002/primary_doc.xml","form_type":"4"}},{"id":2938840,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-18T21:24:01.000Z","date":"2020-12-16","kind":"sale","acquired":false,"shares":50000,"price":0.3,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":". The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4053700,"source":{"system":"sec-edgar","filing":"0001356710-20-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000002/primary_doc.xml","form_type":"4"}},{"id":2945620,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-15T22:40:31.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":50000,"price":0.32,"value":16000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4103700,"source":{"system":"sec-edgar","filing":"0001356710-20-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000001/primary_doc.xml","form_type":"4"}},{"id":2945619,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-15T22:40:31.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":50000,"price":0.3,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4153700,"source":{"system":"sec-edgar","filing":"0001356710-20-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000001/primary_doc.xml","form_type":"4"}},{"id":2945618,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-15T22:40:31.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":50000,"price":0.3,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4203700,"source":{"system":"sec-edgar","filing":"0001356710-20-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000001/primary_doc.xml","form_type":"4"}},{"id":2945617,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-15T22:40:31.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":46300,"price":0.29,"value":13427.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4253700,"source":{"system":"sec-edgar","filing":"0001356710-20-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000001/primary_doc.xml","form_type":"4"}},{"id":2945616,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-15T22:40:31.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":50000,"price":0.29,"value":14500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4300000,"source":{"system":"sec-edgar","filing":"0001356710-20-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000001/primary_doc.xml","form_type":"4"}},{"id":2945615,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-15T22:40:31.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":50000,"price":0.28,"value":14000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4350000,"source":{"system":"sec-edgar","filing":"0001356710-20-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000001/primary_doc.xml","form_type":"4"}},{"id":2945614,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-15T22:40:31.000Z","date":"2020-12-11","kind":"sale","acquired":false,"shares":50000,"price":0.26,"value":13000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4400000,"source":{"system":"sec-edgar","filing":"0001356710-20-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000001/primary_doc.xml","form_type":"4"}},{"id":2945613,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer and Director"}}],"security":"Common Stock","published_at":"2020-12-15T22:40:31.000Z","date":"2020-12-11","kind":"sale","acquired":false,"shares":50000,"price":0.25,"value":12500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2020."}],"balance_after":4450000,"source":{"system":"sec-edgar","filing":"0001356710-20-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000135671020000001/primary_doc.xml","form_type":"4"}},{"id":3122810,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":148702,"kind":"person","name":"Cataldo Tony","position":1,"cik":"0001450565","reported_name":"Cataldo Tony","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"common stock","published_at":"2020-06-04T21:15:28.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":4234320,"price":0.001,"value":4234.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The disposal of the 4,234,320 shares was made to satisfy obligations pursuant to the terms of a Stock Pledge Agreement signed on August 1, 2018."}],"balance_after":6500000,"source":{"system":"sec-edgar","filing":"0000939798-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979820000007/primary_doc.xml","form_type":"4"}},{"id":3150010,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"common stock","published_at":"2020-05-14T17:40:35.000Z","date":"2020-05-13","kind":"sale","acquired":false,"shares":2269708,"price":0.001,"value":2269.708,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The disposal of the 2,269,708 shares was made to satisfy obligations pursuant to the terms of a Stock Pledge Agreement signed on August 1, 2018."}],"balance_after":4500000,"source":{"system":"sec-edgar","filing":"0000939798-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979820000006/primary_doc.xml","form_type":"4"}},{"id":3436950,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":148702,"kind":"person","name":"Cataldo Tony","position":1,"cik":"0001450565","reported_name":"Cataldo Tony","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"common stock","published_at":"2019-08-16T20:57:26.000Z","date":"2019-08-14","kind":"grant","acquired":true,"shares":7000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10734320,"source":{"system":"sec-edgar","filing":"0000939798-19-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979819000031/primary_doc.xml","form_type":"4"}},{"id":3436949,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CFO"}}],"security":"common stock","published_at":"2019-08-16T20:51:22.000Z","date":"2019-08-14","kind":"grant","acquired":true,"shares":4500000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6769707,"source":{"system":"sec-edgar","filing":"0000939798-19-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979819000030/primary_doc.xml","form_type":"4"}},{"id":3589461,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":88034,"kind":"person","name":"Urbanski Raymond W.","position":1,"cik":"0001653096","reported_name":"Urbanski Raymond W.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"common stock","published_at":"2019-03-19T18:38:04.000Z","date":"2019-02-01","kind":"sale","acquired":false,"shares":176980,"price":0.001,"value":176.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The disposal of the 176,980 shares was made to satisfy obligations pursuant to the terms of a Stock Pledge Agreement signed on August 1, 2018."}],"balance_after":1351918,"source":{"system":"sec-edgar","filing":"0000939798-19-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979819000008/primary_doc.xml","form_type":"4"}},{"id":3661857,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":148702,"kind":"person","name":"Cataldo Tony","position":1,"cik":"0001450565","reported_name":"Cataldo Tony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2019-02-13T16:22:54.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":800000,"price":0.001,"value":800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This a stock pledge for nominal consideration in a private transaction for a personal family matter."}],"balance_after":4029600,"source":{"system":"sec-edgar","filing":"0000939798-19-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979819000005/primary_doc.xml","form_type":"4"}},{"id":4146954,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":148702,"kind":"person","name":"Cataldo Tony","position":1,"cik":"0001450565","reported_name":"Cataldo Tony","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"common stock","published_at":"2017-12-02T00:12:59.000Z","date":"2017-11-02","kind":"gift","acquired":false,"shares":3000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1843029,"source":{"system":"sec-edgar","filing":"0000939798-17-000102","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979817000102/primary_doc.xml","form_type":"4"}},{"id":4146953,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":148702,"kind":"person","name":"Cataldo Tony","position":1,"cik":"0001450565","reported_name":"Cataldo Tony","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"common stock","published_at":"2017-12-02T00:12:59.000Z","date":"2017-11-02","kind":"gift","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4843029,"source":{"system":"sec-edgar","filing":"0000939798-17-000102","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979817000102/primary_doc.xml","form_type":"4"}},{"id":4146952,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":148702,"kind":"person","name":"Cataldo Tony","position":1,"cik":"0001450565","reported_name":"Cataldo Tony","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"common stock","published_at":"2017-12-02T00:12:59.000Z","date":"2017-11-02","kind":"gift","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4943029,"source":{"system":"sec-edgar","filing":"0000939798-17-000102","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979817000102/primary_doc.xml","form_type":"4"}},{"id":4146951,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":148702,"kind":"person","name":"Cataldo Tony","position":1,"cik":"0001450565","reported_name":"Cataldo Tony","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"common stock","published_at":"2017-12-02T00:12:59.000Z","date":"2017-09-01","kind":"grant","acquired":true,"shares":5129660,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5143029,"source":{"system":"sec-edgar","filing":"0000939798-17-000102","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979817000102/primary_doc.xml","form_type":"4"}},{"id":4146950,"issuer":{"id":7878,"kind":"organization","name":"GT Biopharma, Inc."},"owners":[{"id":144449,"kind":"person","name":"Weldon Steven W","position":1,"cik":"0001356710","reported_name":"Weldon Steven W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"common stock","published_at":"2017-12-01T22:17:36.000Z","date":"2017-09-01","kind":"grant","acquired":true,"shares":2566835,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2568840,"source":{"system":"sec-edgar","filing":"0000939798-17-000099","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/109657/000093979817000099/primary_doc.xml","form_type":"4"}}]}